Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by ...

Managing Director & Global CEO Umang Vohra expressed confidence in the company's ability to expand, driven by a multi-pronged ...

Profit exceeded Bloomberg estimates by 19.4 per cent, whereas the revenue fell along the expected lens growing 0.28 per cent ...

Indian pharma giant Cipla released its Q4 FY 25 result, wherein it posted a healthy year-on-year growth of 30% in net profit ...

Nifty Pharma major Cipla is likely to deliver a strong set of numbers for the quarter ended March 2025, with broad-based ...

Cipla CEO Umang Vohra discusses challenges in pharmaceutical industry, including US tariffs, with uncertain future ahead.

Pharma giant Cipla announced a significant 30 percent increase in consolidated net profit attributable to shareholders for ...

Along with the Q4 results, Cipla announced a final dividend of Rs 13 per equity share for the financial year 2025, and a ...

Board of directors recommend a final dividend of ₹14 per equity share for FY25 and a special dividend of ₹3 per share ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by ...

Cipla reported a 30% increase in net profit, reaching Rs 1,222 crore in Q4 FY25, fueled by higher sales in India, the US, and ...